Fluticasone propionate/formoterol fumarate in fixed-dose combination for the treatment of asthma

References

• GINA FAQs; 2013. Available from: http://ginasthma.org/FAQs
   Google Scholar
• Fanta CH. Asthma. N Engl J Med 2009;360(10):1002-14
   PubMed Web of Science ®Google Scholar
• van der Wiel E, ten Hacken NH, Postma DS, van den Berge M. Small-airways dysfunction associates with respiratory symptoms and clinical features of asthma: a systematic review. J Allergy Clin Immunol 2013;131(3):646-57
   PubMed Web of Science ®Google Scholar
• Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180(1):59-99
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). GINA report, Global Strategy for Asthma Management and Prevention, updated 2013. Available from: www.ginasthma.org
   Google Scholar
• Demoly P, Annunziata K, Gubba E, Adamek L. Repeated cross-sectional survey of patient-reported asthma control in Europe in the past 5 years. Eur Respir Rev 2012;21(123):66-74
   PubMedGoogle Scholar
• Murphy KR, Meltzer EO, Blaiss MS, et al. Asthma management and control in the United States: results of the 2009 Asthma Insight and Management survey. Allergy Asthma Proc 2012;33(1):54-64
   PubMed Web of Science ®Google Scholar
• Accordini S, Corsico AG, Braggion M, et al. The cost of persistent asthma in Europe: an international population-based study in adults. Int Arch Allergy Immunol 2013;160(1):93-101
   PubMed Web of Science ®Google Scholar
• Meltzer EO, Blaiss MS, Nathan RA, et al. Asthma burden in the United States: results of the 2009 Asthma Insight and Management survey. Allergy Asthma Proc 2012;33(1):36-46
   PubMed Web of Science ®Google Scholar
• British Thoracic Society (BTS), Scottish Intercollegiate Guidelines Network (SIGN), British Guideline on the Management of Asthma. A national clinical guideline. May 2008. Available from: http://www.sign.ac.uk/guidelines/fulltext/101/index.html
   Google Scholar
• National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. 2007. Available from: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf
   Google Scholar
• Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma-Summary Report 2007. J Allergy Clin Immunol 2007;120(5 Suppl):S94-138
   PubMed Web of Science ®Google Scholar
• Tamm M, Richards DH, Beghe B, Fabbri L. Inhaled corticosteroid and long-acting beta2-agonist pharmacological profiles: effective asthma therapy in practice. Respir Med 2012;106(suppl 1):S9-19
   Web of Science ®Google Scholar
• Kelly HW. Comparison of inhaled corticosteroids: an update. Ann Pharmacother 2009;43(3):519-27
   PubMed Web of Science ®Google Scholar
• Chrystyn H, Price D. Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Prim Care Respir J 2009;18(4):243-9
   PubMedGoogle Scholar
• Haughney J, Price D, Barnes NC, et al. Choosing inhaler devices for people with asthma: current knowledge and outstanding research needs. Respir Med 2010;104(9):1237-45
   PubMed Web of Science ®Google Scholar
• Papi A, Haughney J, Virchow JC, et al. Inhaler devices for asthma: a call for action in a neglected field. Eur Respir J 2011;37(5):982-5
   PubMed Web of Science ®Google Scholar
• Small M, Anderson P, Vickers A, et al. Importance of inhaler-device satisfaction in asthma treatment: real-world observations of physician-observed compliance and clinical/patient-reported outcomes. Adv Ther 2011;28(3):202-12
   PubMed Web of Science ®Google Scholar
• Price D, Chrystyn H, Kaplan A, et al. Effectiveness of same versus mixed asthma inhaler devices: a retrospective observational study in primary care. Allergy Asthma Immunol Res 2012;4(4):184-91
   PubMed Web of Science ®Google Scholar
• Marceau C, Lemiere C, Berbiche D, et al. Persistence, adherence, and effectiveness of combination therapy among adult patients with asthma. J Allergy Clin Immunol 2006;118(3):574-81
   PubMed Web of Science ®Google Scholar
• Stoloff SW, Stempel DA, Meyer J, et al. Improved refill persistence with fluticasone propionate and salmeterol in a single inhaler compared with other controller therapies. J Allergy Clin Immunol 2004;113(2):245-51
   PubMed Web of Science ®Google Scholar
• Murphy KR, Bender BG. Treatment of moderate to severe asthma: patient perspectives on combination inhaler therapy and implications for adherence. J Asthma Allergy 2009;2:63-72
   PubMedGoogle Scholar
• US Food and Drug Administration (FDA) Long-Acting Beta Agonist (LABA) Information. Available from: http://www.fda.gov/drugs/DrugSafety/InformationbyDrugClass/ucm199565.htm
   Google Scholar
• Chowdhury BA, Seymour SM, Levenson MS. Assessing the safety of adding LABAs to inhaled corticosteroids for treating asthma. N Engl J Med 2011;364(26):2473-5
   PubMed Web of Science ®Google Scholar
• Sears MR. Safety of long-acting beta-agonists: are new data really required? Chest 2009;136(2):604-7
   Google Scholar
• Electronic Medicines Compendium (eMC) Flutiform 50 microgram/5 microgram, 125 microgram/5 microgram and 250 microgram/10 microgram per actuation pressurised inhalation, suspension. Available from: http://www.medicines.org.uk/emc/medicine/26954
   Google Scholar
• Dissanayake S, Grothe B, Kaiser K. Fluticasone/formoterol: a new single-aerosol combination therapy for patients with asthma. Respir Med 2012;106(Suppl 1):S20-8
   PubMedGoogle Scholar
• McKeage K. Fluticasone propionate/formoterol fumarate: a review of its use in persistent asthma. Drugs 2013;73(2):195-206
   PubMedGoogle Scholar
• Adams NP, Bestall JC, Jones P, et al. Fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev 2008;(4):CD003534
   Google Scholar
• Adams NP, Bestall JC, Lasserson TJ, et al. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev 2008;(4):CD003135
   Google Scholar
• Price D, Bousquet J. Real-world perceptions of inhaled corticosteroid/long-acting beta(2)-agonist combinations in the treatment of asthma. Respir Med 2012;106(Suppl 1):S4-8
   Google Scholar
• Politiek MJ, Boorsma M, Aalbers R. Comparison of formoterol, salbutamol and salmeterol in methacholine-induced severe bronchoconstriction. Eur Respir J 1999;13(5):988-92
   PubMed Web of Science ®Google Scholar
• Palmqvist M, Persson G, Lazer L, et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur Respir J 1997;10(11):2484-9
   PubMed Web of Science ®Google Scholar
• Derendorf H, Nave R, Drollmann A, et al. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006;28(5):1042-50
   PubMed Web of Science ®Google Scholar
• Barnes NC. The properties of inhaled corticosteroids: similarities and differences. Prim Care Respir J 2007;16(3):149-54
   Google Scholar
• Palmqvist M, Ibsen T, Mellen A, Lotvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients. Am J Respir Crit Care Med 1999;160(1):244-9
   PubMed Web of Science ®Google Scholar
• Welsh EJ, Cates CJ. Formoterol versus short-acting beta-agonists as relief medication for adults and children with asthma. Cochrane Database Syst Rev 2010;(9):CD008418
   Google Scholar
• Aalbers R, Brusselle G, Mciver T, et al. Onset of bronchodilation with fluticasone/formoterol combination versus fluticasone/salmeterol in an open-label, randomized study. Adv Ther 2012;29(11):958-69
   PubMedGoogle Scholar
• Kanniess F, Diamant Z, Lomax M, Jain M. Effects of low- and high-dose fluticasone/formoterol combination thereapy on AMP challenge in asthmatic patients [abstract]. Annual Congress of the European Respiratory Society; 7–11 September 2013; Barcelona, Spain
   Google Scholar
• Tamm M, Kaiser K, Grothe B, Lomax M. Effects on adrenal function of a new combination of fluticasone propionate/formoterol fumarate administered to asthmatic patients and healthy subjects [abstract no. P4010]. 21st Annual Congress of the European Respiratory Society; 24–28 September 2011; Amsterdam
   Google Scholar
• Priestley A, Woodward J, McIver T, Mundin G. Effect of high-dose inhaled fluticasone/formoterol combination therapy compared with its separate components on hypothalamo-pituitary-adrenal (HPA) axis function [abstract no.1553]. Allergy 2011;66(Suppl 94):586
   Google Scholar
• Heyder J. Deposition of inhaled particles in the human respiratory tract and consequences for regional targeting in respiratory drug delivery. Proc Am Thorac Soc 2004;1(4):315-20
   PubMedGoogle Scholar
• Usmani OS, Biddiscombe MF, Barnes PJ. Regional lung deposition and bronchodilator response as a function of beta2-agonist particle size. Am J Respir Crit Care Med 2005;172(12):1497-504
   PubMed Web of Science ®Google Scholar
• Pritchard JN. The influence of lung deposition on clinical response. J Aerosol Med 2001;14(Suppl 1):S19-26
   PubMedGoogle Scholar
• Johal B, Howald M, Fischer M, et al. Fine particle profile of fluticasone propionate/formoterol fumarate versus other combination products: the DIFFUSE study. Comb Prod Ther 2013;3(1-2):39-51
   Google Scholar
• De Backer W, Devolder A, Poli G, et al. Lung deposition of BDP/formoterol HFA pMDI in healthy volunteers, asthmatic, and COPD patients. J Aerosol Med Pulm Drug Deliv 2010;23(3):137-48
   PubMed Web of Science ®Google Scholar
• Mollmann H, Wagner M, Meibohm B, et al. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol 1998;53(6):459-67
   Google Scholar
• Holliday SM, Faulds D, Sorkin EM. Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma. Drugs 1994;47(2):318-31
   PubMedGoogle Scholar
• Bartow RA, Brogden RN. Formoterol. An update of its pharmacological properties and therapeutic efficacy in the management of asthma. Drugs 1998;55(2):303-22
   Google Scholar
• Nathan RA, D’Urzo A, Blazhko V, Kaiser K. Safety and efficacy of fluticasone/formoterol combination therapy in adolescent and adult patients with mild-to-moderate asthma: a randomised controlled trial. BMC Pulm Med 2012;12:67
   PubMed Web of Science ®Google Scholar
• Corren J, Mansfield LE, Pertseva T, et al. Efficacy and safety of fluticasone/formoterol combination therapy in patients with moderate-to-severe asthma. Respir Med 2013;107(2):180-95
   PubMed Web of Science ®Google Scholar
• Pearlman DS, Laforce CF, Kaiser K. Fluticasone/Formoterol combination therapy compared with monotherapy in adolescent and adult patients with mild to moderate asthma. Clin Ther 2013;35(7):950-66
   PubMedGoogle Scholar
• Pertseva T, Dissanayake S, Kaiser K. Superiority of fluticasone propionate/formoterol fumarate versus fluticasone propionate alone in patients with moderate-to-severe asthma: a randomised controlled trial. Curr Med Res Opin 2013;29(10):1357-69
   PubMed Web of Science ®Google Scholar
• Bodzenta-Lukaszyk A, Pulka G, Dymek A, et al. Efficacy and safety of fluticasone and formoterol in a single pressurized metered dose inhaler. Respir Med 2011;105(5):674-682
   PubMed Web of Science ®Google Scholar
• Bodzenta-Lukaszyk A, Van Noord J, Schroder-Babo W, et al. Efficacy and safety profile of fluticasone/formoterol combination therapy compared to its individual components administered concurrently in asthma: a randomised controlled trial. Curr Med Res Opin 2013;29(5):579-88
   PubMed Web of Science ®Google Scholar
• Bodzenta-Lukaszyk A, Dymek A, Mcaulay K, Mansikka H. Fluticasone/formoterol combination therapy is as effective as fluticasone/salmeterol in the treatment of asthma, but has a more rapid onset of action: an open-label, randomized study. BMC Pulm Med 2011;11:28
   PubMed Web of Science ®Google Scholar
• Bodzenta-Lukaszyk A, Buhl R, Balint B, et al. Fluticasone/formoterol combination therapy versus budesonide/formoterol for the treatment of asthma: a randomized, controlled, non-inferiority trial of efficacy and safety. J Asthma 2012;49(10):1060-70
   PubMedGoogle Scholar
• Papi A, Price D, Sastre J, et al. Fluticasone propionate/formoterol fumarate improves asthma control and reduces exacerbations compared with fluticasone. Poster P2816. Annual Congress of the European Respiratory Society (ERS); Barcelona; 2013
   Google Scholar
• Mansur AH, Kaiser K. Long-term safety and efficacy of fluticasone/formoterol combination therapy in asthma. J Aerosol Med Pulm Drug Deliv 2013;26(4):190-9
   PubMed Web of Science ®Google Scholar
• Cates CJ, Jaeschke R, Schmidt S, Ferrer M. Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2013;6:CD006924
   Google Scholar
• Nelson H, Bonuccelli C, Radner F, et al. Safety of formoterol in patients with asthma: combined analysis of data from double-blind, randomized controlled trials. J Allergy Clin Immunol 2010;125(2):390-6. e398
   Google Scholar
• Cates CJ, Lasserson TJ. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Cochrane Database Syst Rev 2010;(1):CD007694
   Google Scholar
• Haughney J, Price D, Kaplan A, et al. Achieving asthma control in practice: understanding the reasons for poor control. Respir Med 2008;102(12):1681-93
   PubMed Web of Science ®Google Scholar
• Harding G, Leidy NK, Meddis D, et al. Interpreting clinical trial results of patient-perceived onset of effect in asthma: methods and results of a Delphi panel. Curr Med Res Opin 2009;25(6):1563-71
   PubMed Web of Science ®Google Scholar
• Leidy NK, Gutierrez B, Lampl K, et al. Can patients with asthma feel inhaler therapy working right away? Two clinical trials testing the effect of timing of assessment on patient perception. J Asthma 2009;46(10):1006-12
   Google Scholar
• Hauber AB, Mohamed AF, Johnson FR, et al. Quantifying asthma patient preferences for onset of effect of combination inhaled corticosteroids and long-acting beta2-agonist maintenance medications. Allergy Asthma Proc 2009;30(2):139-47
   PubMedGoogle Scholar
• Bousquet J, Winchester C, Papi A, et al. Inhaled corticosteroid/long-acting beta(2)-agonist combination therapy for asthma: attitudes of specialists in Europe. Int Arch Allergy Immunol 2012;157(3):303-10
   Google Scholar
• Price D, Roche N, Christian Virchow J, et al. Device type and real-world effectiveness of asthma combination therapy: an observational study. Respir Med 2011;105(10):1457-66
   PubMed Web of Science ®Google Scholar
• Leach CL, Davidson PJ, Hasselquist BE, Boudreau RJ. Lung deposition of hydrofluoroalkane-134a beclomethasone is greater than that of chlorofluorocarbon fluticasone and chlorofluorocarbon beclomethasone: a cross-over study in healthy volunteers. Chest 2002;122(2):510-16
   PubMed Web of Science ®Google Scholar
• Leach CL, Kuehl PJ, Chand R, et al. Characterization of respiratory deposition of fluticasone-salmeterol hydrofluoroalkane-134a and hydrofluoroalkane-134a beclomethasone in asthmatic patients. Ann Allergy Asthma Immunol 2012;108(3):195-200
   PubMed Web of Science ®Google Scholar
• Haussermann S, Acerbi D, Brand P, et al. Lung deposition of formoterol HFA (Atimos/Forair) in healthy volunteers, asthmatic and COPD patients. J Aerosol Med 2007;20(3):331-41
   PubMedGoogle Scholar
• Vos W, De Backer J, Poli G, et al. Novel functional imaging of changes in small airways of patients treated with extrafine beclomethasone/formoterol. Respiration 2013;86(5):393-401
   PubMed Web of Science ®Google Scholar
• Price D, Martin RJ, Barnes N, et al. Prescribing practices and asthma control with hydrofluoroalkane-beclomethasone and fluticasone: a real-world observational study. J Allergy Clin Immunol 2010;126(3):511-18. e511-510
   PubMed Web of Science ®Google Scholar
• Barnes N, Price D, Colice G, et al. Asthma control with extrafine-particle hydrofluoroalkane-beclometasone vs large-particle chlorofluorocarbon-beclometasone: a real-world observational study. Clin Exp Allergy 2011;41(11):1521-32
   PubMedGoogle Scholar
• Rigazio A, Buck P, Burden A, et al. Integration of dose-counters into metered-dose inhalers may reduce incidence of respiratory-related emergency room visits [abstract]. American College of Allergy, Asthma & Immunology (ACAAI) Annual Meeting; Baltimore; 2013
   Google Scholar
• Krishnan JA, Schatz M, Apter AJ. A call for action: comparative effectiveness research in asthma. J Allergy Clin Immunol 2011;127(1):123-7
   Google Scholar
• Price D, Bjermer L, Haughney J, et al. Real-life asthma strategies: the missing piece in the jigsaw. Treatment Strategies - Respiratory 2012;3(2):37-46
   Google Scholar
• Price D, Chisholm A, Van Der Molen T, et al. Reassessing the evidence hierarchy in asthma: evaluating comparative effectiveness. Curr Allergy Asthma Rep 2011;11(6):526-38
   PubMed Web of Science ®Google Scholar
• Lemanske RF Jr, Busse WW. Asthma: clinical expression and molecular mechanisms. J Allergy Clin Immunol 2010;125(2 Suppl 2):S95-102
   PubMed Web of Science ®Google Scholar
• Carolan BJ, Sutherland ER. Clinical phenotypes of chronic obstructive pulmonary disease and asthma: recent advances. J Allergy Clin Immunol 2013;131(3):627-34
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. A service of the U.S. National Institutes of Health. Available from: http://clinicaltrials.gov/
   Google Scholar
• Respiratory Effectiveness Group. Available from: http://www.effectivenessevaluation.org/
   Google Scholar
• Price D, Bateman ED, Chisholm A, et al. Complementing the randomized controlled trial evidence base: evolution not revolution. Ann Am Thor Soc 2014;11(Suppl 2):s92-8
   PubMedGoogle Scholar
• Conway PH, Clancy C. Comparative-effectiveness research--implications of the Federal Coordinating Council’s report. N Engl J Med 2009;361(4):328-30
   PubMed Web of Science ®Google Scholar
• Busse WW, Morgan WJ, Taggart V, Togias A. Asthma outcomes workshop: overview. J Allergy Clin Immunol 2012;129(3 Suppl):S1-8
   Google Scholar